MetaVia Inc. (MTVA)
NASDAQ: MTVA
· Real-Time Price · USD
0.75
-0.01 (-1.45%)
At close: May 01, 2025, 3:53 PM
0.81
8.43%
Pre-market: May 02, 2025, 07:15 AM EDT
-1.45% (1D)
| Bid | 0.74 |
| Market Cap | 7.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.59M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.81 |
| Volume | 52,295 |
| Avg. Volume (20D) | 491,268 |
| Open | 0.77 |
| Previous Close | 0.76 |
| Day's Range | 0.74 - 0.77 |
| 52-Week Range | 0.65 - 5.30 |
| Beta | 0.22 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 5, 2016
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MTVA
Website https://www.metaviatx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MTVA stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1506.43% from the latest price.
Stock Forecasts2 weeks ago
-55.98%
MetaVia shares are trading lower. The company anno...
Unlock content with
Pro Subscription